UMass Vaccine Candidate Lures $600K in Research, Patent Option

BioVeris Corp. of Maryland has optioned from the University of Massachusetts at Amherst exclusive patent rights to a vaccine candidate aimed at chlamydia, a sexually transmitted disease that affects 3 million Americans a year. Under the agreement with UMass, BioVeris acquired a first option for exclusive rights to commercialize products for possible use in the prevention, diagnosis and treatment of chlamydia, the most frequently reported infectious disease in the United States.

()a href="http://www.masshightech.com/displayarticledetail.asp?Art_ID=68738" target="_blank">Mass High Tech